This study is for people with a type of lung cancer called Metastatic Non-Small Cell Lung Cancer (NSCLC). "Metastatic" means the cancer has spread, and "non-small cell" is a common type of lung cancer. We're testing a new medicine called Ivonescimab with chemotherapy and comparing it to another treatment called Pembrolizumab with chemotherapy. The main goal is to see how long patients live and how long the cancer stays under control. We'll also look at how well patients respond and the safety of the treatments.

• Study involves around 1600 patients, split into two groups based on cancer type.
• Participants must be at least 18 years old and in good health.
• No previous treatments for this type of lung cancer are allowed.

If you join, you will be randomly chosen to get one of the treatments and will be closely monitored. Before joining, you need to have tests to confirm what type of lung cancer you have. The study checks for safety and effectiveness, but there are risks involved. Always talk to your doctor to understand the potential benefits and risks.